Concomitant orally administered drugs

Concomitant orally administered drugs is a clinical and pharmacological designation rather than a specific biological target, receptor, or enzyme. It refers to the simultaneous administration of multiple medications, a common occurrence in patients with comorbidities, which can lead to significant drug-drug interactions (DDIs) (FDA, 2020). These interactions may be pharmacokinetic, affecting the absorption, distribution, metabolism, or excretion (ADME) of a drug, or pharmacodynamic, where drugs have overlapping or opposing effects on the same physiological system (StatPearls, 2023). For example, one drug may inhibit a cytochrome P450 enzyme required for the metabolism of another, leading to toxic plasma levels (Merck Manual, 2022). Understanding the impact of concomitant medications is vital for drug safety, as polypharmacy is a major risk factor for adverse drug events and therapeutic failure. In the context of drug development, this term highlights the necessity of conducting interaction studies to establish safe prescribing guidelines (EMA, 2017). It is a critical variable in clinical trial design and post-marketing surveillance rather than a specific protein or pathway.

Other names

Concomitant medicationsCo-administered drugsPolypharmacyCon-meds

Not applicable